Trial Profile
Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluoropyrimidine derivatives; Fluorouracil; Folinic acid; Irinotecan; Mitomycin; Oxaliplatin
- Indications Adenocarcinoma; Cancer metastases; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CAIRO-6
- 03 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 05 May 2017 Planned primary completion date changed from 1 Jan 2024 to 1 Aug 2024.
- 05 May 2017 Status changed from not yet recruiting to recruiting.